ARCHIVES

Trifluridine and Tipiracil Hydrochloride Increase OS, PFS in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Ovarian Cancer Symptom Indices May Need to be Re-Evaluated

January 27, 2012

Obituary: Joseph Burchenal, 93, A Leader In Cancer Drug Development at MSKCC.

March 17, 2006

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

Don’t Blame FDA For All Problems, Broder Says

September 7, 1990

In Brief: Terry To Leave NCI for Job As VP Of Revlon Health Care Group; NCI Tracking Source Of Breakthroughs

June 18, 1982

NIH To Site Visit Animal Facilities

March 18, 1983